Skip to main content

Clostridial-directed enzyme prodrug therapy (cdept): a novel approach to cancer treatment.

Objective

Current systems for delivering therapeutic genes to tumours suffer from a number of serious deficiencies, most notably a lack of specificity for cancer cells. Here we propose an innovative solution to the problem based on the use of the spores of a harmless, non-pathogenic Clostridium species, Clostridium acetobutylicum. Intravenously injected clostridia spores localise to, and exclusively germinate in, the hypoxic regions of solid tumours. The spores are incapable of germinating in healthy tissue. We will engineer this harmless organism such that it produces a variety of prod rug-converting enzymes and assess their anti-tumour effects in a rat tumour model. New, more efficient enzymes and prod rugs will be developed. To increase safety, the clostridia host will be derivative such that it cannot speculate outside of the confines of the laboratory "flask".

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

UNIVERSITY OF NOTTINGHAM
Address
Queen's Medical Centre - University Hospital
NG7 2UH Nottingham
United Kingdom

Participants (4)

ENACT PHARMA PLC
United Kingdom
Address
Centre One 8, Lysander Way, Old Sarum Park
SP4 6BU Salisbury
UNIVERSITY HOSPITAL MAASTRICHT
Netherlands
Address
Peter Debyelaan 25
6229 HX Maastricht
UNIVERSITY OF ULM
Germany
Address
Albert-einstein-allee 11
89081 Ulm
UPPSALA IMANET AB
Sweden
Address
Uppsala Academic Hospital, Entrance 86
75109 Uppsala